Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.

Human molecular genetics - 1 Mar 2012

Johri Ashu, Calingasan Noel Y, Hennessey Thomas M, Sharma Abhijeet, Yang Lichuan, Wille Elizabeth, Chandra Abhishek, Beal M Flint

Abstract excerpt

There is substantial evidence that impairment of peroxisome proliferator-activated receptor (PPAR)-γ-coactivator 1α (PGC-1α) levels and activity play an important role in Huntington's disease (HD) pathogenesis. We tested whether pharmacologic treatment with the pan-PPAR agonist bezafibrate would correct a deficiency of PGC-1α and exert beneficial effects in a transgenic mouse model of HD. We found that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adipose Tissue, Brown
Share to Corpus Striatum

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gliosis

Share to Mitochondria, Muscle

Share to Muscle Fibers, Skeletal

Share to Neuroprotective Agents

Share to Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha

Share to PPAR gamma

Source

Open in PubMed Open full text

Identifiers

PMID: 22095692
DOI: 10.1093/hmg/ddr541
PMCID: PMC3277311

Genes

PGC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.PMID 22095692Read ↗

Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington’s diseaseSemantic proximity Read ↗

PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.Semantic proximity Read ↗

Dysregulation of PGC-1α-Dependent Transcriptional Programs in Neurological and Developmental Disorders: Therapeutic Challenges and OpportunitiesSemantic proximity Read ↗

Neuroprotective effects of <scp>PPAR</scp>‐γ agonist rosiglitazone in N171‐82Q mouse model of Huntington's diseaseSemantic proximity Read ↗

PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disordersSemantic proximity Read ↗

PGC-1α sparks the fire of neuroprotection against neurodegenerative disordersSemantic proximity Read ↗

Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s diseaseSemantic proximity Read ↗

Glitazones, PPAR-γ and NeuroprotectionSemantic proximity Read ↗

Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptorsSemantic proximity Read ↗

Truncated peroxisome proliferator-activated receptor-γ coactivator 1α splice variant is severely altered in Huntington's disease.Semantic proximity Read ↗

Cannabidiol ameliorates mitochondrial disease via PPARγ activationSemantic proximity Read ↗

PGC-1α, mitochondrial dysfunction, and Huntington's diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.